NCT06648473View on ClinicalTrials.gov

Repeatability of Magnetic Resonance Imaging in Patients With IDH1 Mutant Glioma on Ivosidenib

NANot yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 1, 2026

Primary Completion Date

December 1, 2027

Study Completion Date

December 1, 2027

Conditions
Low Grade Glioma of Brain
Interventions
DIAGNOSTIC_TEST

MRI Scan

Subjects will begin the MRI with T1-pre, T2w, and volumetric 3D FLAIR images being obtained. The subject will be brought out of the MRI magnet and moved into a seated position and will then have a standard Brain Tumor Imaging Protocol MRI scan.

Trial Locations (1)

27710

Duke University Medical Center, Durham

Sponsors

Lead Sponsor

Duke University
All Listed Sponsors
collaborator

Institut de Recherches Internationales Servier

OTHER

lead

Duke University

OTHER

NCT06648473 - Repeatability of Magnetic Resonance Imaging in Patients With IDH1 Mutant Glioma on Ivosidenib | Biotech Hunter | Biotech Hunter